HHS Stops U.S. Distribution Of Lilly’s Bamlanivimab For COVID-19

HHS will stop distributing Eli Lilly’s COVID-19 monoclonal antibody bamlanivimab as a single therapy across the United States due to increased spread of COVID-19 variants that are resistant to bamlanivimab when it’s administered by itself, the department announced Wednesday (March 24) . HHS will still distribute Lilly’s bamlanivimab in conjunction with etesevimab to be used as part of an antibody cocktail, and etesevimab can be ordered on its own to pair with any supply of bamlanivimab that sites already have...